These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 31181727)

  • 21. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.
    Tsai YC; Zeng T; Abou-Kheir W; Yeh HL; Yin JJ; Lee YC; Chen WY; Liu YN
    Mol Cancer; 2018 Feb; 17(1):42. PubMed ID: 29455655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
    Chen WY; Tsai YC; Siu MK; Yeh HL; Chen CL; Yin JJ; Huang J; Liu YN
    Oncogene; 2017 Nov; 36(45):6213-6224. PubMed ID: 28692046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of SPDEF expression by DNA methylation in advanced prostate cancer.
    Vatanmakanian M; Steffan JJ; Koul S; Ochoa AC; Chaturvedi LS; Koul HK
    Front Endocrinol (Lausanne); 2023; 14():1156120. PubMed ID: 37900138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
    Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
    Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.
    Launonen KM; Paakinaho V; Sigismondo G; Malinen M; Sironen R; Hartikainen JM; Laakso H; Visakorpi T; Krijgsveld J; Niskanen EA; Palvimo JJ
    Oncogene; 2021 Jul; 40(27):4567-4579. PubMed ID: 34127815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.
    Jian J; Wang X; Zhang J; Zhou C; Hou X; Huang Y; Hou J; Lin Y; Wei X
    Front Endocrinol (Lausanne); 2024; 15():1360430. PubMed ID: 38887275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
    Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
    Parolia A; Venalainen E; Xue H; Mather R; Lin D; Wu R; Pucci P; Rogalski J; Evans JR; Feng F; Collins CC; Wang Y; Crea F
    Mol Oncol; 2019 May; 13(5):1121-1136. PubMed ID: 30776192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
    Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The roles of microRNAs in the progression of castration-resistant prostate cancer.
    Kojima S; Goto Y; Naya Y
    J Hum Genet; 2017 Jan; 62(1):25-31. PubMed ID: 27278789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY; Dong Q; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
    Ta HQ; Ivey ML; Frierson HF; Conaway MR; Dziegielewski J; Larner JM; Gioeli D
    Cancer Res; 2015 Dec; 75(23):5093-105. PubMed ID: 26573794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
    Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
    Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.